Chargement en cours...
Galactosylation variations in marketed therapeutic antibodies
There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Ch...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Landes Bioscience
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3355481/ https://ncbi.nlm.nih.gov/pubmed/22531450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.19868 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|